Frankfurt - Delayed Quote EUR

Alphamab Oncology (3NK.F)

Compare
0.2740 -0.0040 (-1.44%)
As of 8:06 AM GMT+2. Market Open.
Loading Chart for 3NK.F
DELL
  • Previous Close 0.2780
  • Open 0.2740
  • Bid 0.2700 x --
  • Ask 0.3520 x --
  • Day's Range 0.2740 - 0.2740
  • 52 Week Range 0.2520 - 1.5700
  • Volume 50,939
  • Avg. Volume 837
  • Market Cap (intraday) 303.888M
  • Beta (5Y Monthly) 0.27
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date Mar 28, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase III clinical trials for treatment of HER2-positive breast cancer; and phase I and II clinical trial treatment of heavily pre-treated HER2 cancers, as well as Phase II clinical trial to treat unreselectable or metastatic HER2-positive solid tumors. The company's product pipeline also comprises KN035, an injectable PD-L1 inhibitor that is in phase III clinical trials for neoadjuvant/adjuvant treatment of non-small cell lung cancer and endometrial cancer; and KN019, a CTLA-4-based immunosuppressant fusion protein, for auto-immune diseases and oncology treatment-induced immune disorders. In addition, its product pipeline also includes KN052, a PD-L1/OX40 bispecific antibody that prevents the immune escape of tumor cells; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate that is in phase I/II clinical trial for the treatment of HER2-expressing advanced or metastatic solid tumors; and JSKN033, a subcutaneous antibody-drug conjugate to treat HER2-expressing advanced or metastatic solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.

www.alphamabonc.com

435

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 3NK.F

Performance Overview: 3NK.F

Trailing total returns as of 6/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

3NK.F
63.47%
HANG SENG INDEX
5.21%

1-Year Return

3NK.F
74.15%
HANG SENG INDEX
10.50%

3-Year Return

3NK.F
87.88%
HANG SENG INDEX
36.93%

5-Year Return

3NK.F
83.29%
HANG SENG INDEX
35.58%

Compare To: 3NK.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 3NK.F

Valuation Measures

Annual
As of 6/14/2024
  • Market Cap

    308.32M

  • Enterprise Value

    157.62M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    9.31

  • Price/Book (mrq)

    1.22

  • Enterprise Value/Revenue

    5.50

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -96.26%

  • Return on Assets (ttm)

    -9.50%

  • Return on Equity (ttm)

    -13.04%

  • Revenue (ttm)

    218.77M

  • Net Income Avi to Common (ttm)

    -210.59M

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.41B

  • Total Debt/Equity (mrq)

    15.38%

  • Levered Free Cash Flow (ttm)

    -179.06M

Research Analysis: 3NK.F

Company Insights: 3NK.F

Research Reports: 3NK.F